Introduction – Addressing Core Industry Needs and Solutions
Oncologists, cardiologists, and nuclear medicine physicians face a critical diagnostic challenge: conventional imaging (CT, MRI, ultrasound) detects anatomical changes but cannot identify molecular markers of disease (cancer cell surface antigens, amyloid plaques, perfusion defects). This limits early diagnosis, precise staging, and treatment response assessment. Radionuclide drug conjugates (RDCs) are a new type of diagnostic and therapeutic drug that combines the advantages of precise targeting and powerful killing. Nuclear medicine/radiopharmaceuticals refer to radioactive isotope preparations or a special type of medical drugs labeled with radioactive isotopes. Unlike tumor radiotherapy, nuclear medicine can radiate from the inside out at the site that needs to be treated, while radiotherapy is radiation delivered from the outside in. When the same radiation dose is given, nuclear medicine can target the target site more directly. RDC combines radionuclides with ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators. After the targeted carrier recognizes the tumor cells, it transports the carried nuclides to the location of the target cells, achieving early and specific diagnosis of the disease at the molecular level. Diagnostic RDCs use positron emission tomography (PET – Ga-68, F-18, Cu-64) or single-photon emission computed tomography (SPECT – Tc-99m, In-111, I-123) isotopes for high-sensitivity, whole-body molecular imaging.
Global Leading Market Research Publisher QYResearch announces the release of its latest report *“Diagnostic Radionuclide Drug Conjugates (RDCs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Diagnostic Radionuclide Drug Conjugates (RDCs) market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Diagnostic Radionuclide Drug Conjugates (RDCs) was estimated to be worth US$ 5,265 million in 2025 and is projected to reach US$ 11,160 million, growing at a CAGR of 11.5% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6091571/diagnostic-radionuclide-drug-conjugates–rdcs
1. Core Market Drivers and Theranostic Paradigm
The global diagnostic RDC market is projected to grow at 11.5% CAGR to US$11.16B by 2032, driven by theranostics (same ligand for diagnosis + therapy – e.g., PSMA for prostate cancer, SSTR for neuroendocrine tumors), PET/CT and PET/MRI expansion (20,000+ PET scanners globally), and RDC advantages over ADC (no endocytosis required, better resistance, simpler theranostics).
Recent data (Q4 2024–Q1 2026):
- RDC advantages: (1) multiple ligand formats (antibody, peptide, small molecule – ADC only antibody), (2) no endocytosis required (radiation kills from outside cell), (3) better drug resistance (bystander effect kills antigen-negative cells), (4) theranostics (diagnostic + therapeutic isotope on same ligand).
- Key diagnostic isotopes: Ga-68 (PET, 68 min half-life), F-18 (PET, 110 min), Cu-64 (PET, 12.7h), Tc-99m (SPECT, 6h), I-123 (SPECT, 13h), In-111 (SPECT, 2.8 days).
- Key targets: PSMA (prostate cancer), SSTR (neuroendocrine tumors), HER2 (breast cancer), PD-L1 (immunotherapy patient selection), FAP (cancer-associated fibroblasts), amyloid-β (Alzheimer’s).
2. Segmentation: Ligand Type and Application Verticals
- Antibody-conjugated Nuclear Medicines (ARC) : Largest segment (45% market share). High specificity, long circulation half-life (days). For targets with high expression, slow turnover. Price: $2,000-10,000 per dose. Best for: HER2 (breast cancer), PSMA (prostate), CD20 (lymphoma), PD-L1. Vendors: Novartis, Bayer, BMS, J&J.
- Peptide-conjugated Nuclear Medicines (PRC) : 35% share. Faster clearance (hours), better tumor penetration (smaller size), ideal for theranostics (diagnostic + therapeutic). Price: $1,500-5,000 per dose. Best for: SSTR (neuroendocrine tumors – NETs), PSMA (prostate cancer), FAP (cancer-associated fibroblasts). Vendors: Novartis (Lutathera, Pluvicto), Grand Pharma, China Isotope & Radiation, Yantai Dongcheng, Kelun-Biotech, Hengrui, SmartNuclide, Full-Life, Baheal, Yunnan Baiyao, TOT Biopharm, Nuoyu, Foshan Ruidio, Chengdu Yunke, Shandong Andike, Hexin, Sinotau.
- Small Molecule Conjugated Nuclear Medicines (SMRC) : 20% share (fastest-growing at 15% CAGR). Smallest size, fastest clearance (minutes-hours), ideal for same-day imaging. Price: $500-2,000 per dose. Best for: FAPI (fibroblast activation protein – pan-cancer), PSMA (prostate). Vendors: AstraZeneca, Eli Lilly.
- By Application:
- Prostate Cancer: Largest segment (25% of revenue). PSMA-targeted RDCs (Ga-68 PSMA-11, F-18 DCFPyL). PET/CT for staging, biochemical recurrence detection.
- Neuroendocrine Tumors (NETs): 20% share. SSTR-targeted RDCs (Ga-68 DOTATATE, Cu-64 DOTATATE). PET/CT for diagnosis, staging, theranostics (Lutathera therapy).
- Breast Cancer: 15% share. HER2-targeted RDCs (Zr-89 trastuzumab, F-18 HER2). For HER2 status assessment, treatment selection.
- Lung Cancer: 10% share. PD-L1, EGFR, FAPI. Immunotherapy patient selection.
- Cardiovascular: 5% share (myocardial perfusion, amyloidosis).
- Glioma/Brain: 5% share (amino acid transport – F-18 FET, F-18 FDOPA).
- Liver Cancer, Pancreatic Cancer, Other: 20% share.
3. Industry Vertical Differentiation: RDC vs. ADC vs. Traditional Imaging
| Parameter | Diagnostic RDC | ADC (Antibody-Drug Conjugate) | Traditional Imaging (CT/MRI) |
|---|---|---|---|
| Mechanism | Radionuclide decays → gamma/photon detection (PET/SPECT) | Cytotoxic payload released after endocytosis | Anatomical imaging |
| Endocytosis required? | No (radiation kills from outside) | Yes (payload requires internalization) | N/A |
| Bystander effect | Yes (radiation kills antigen-negative neighbors) | No (requires antigen expression) | N/A |
| Drug resistance | Better (kills regardless of antigen expression) | Poor (antigen loss leads to resistance) | N/A |
| Theranostics (Dx + Tx) | Yes (same ligand, different isotope) | No (diagnostic ADC not standard) | No |
| Ligand size | Antibody (150kDa), peptide (1-5kDa), small molecule (<1kDa) | Antibody only (150kDa) | N/A |
| Detection sensitivity | pM (picomolar) | N/A | mm (millimeter) |
| Molecular information | Yes (target expression, density) | No | No |
| Cost per scan | $500-10,000 | $10,000-50,000 (therapy) | $500-3,000 |
Unlike traditional imaging (anatomical, mm resolution), diagnostic RDCs provide molecular information (target expression, density) at pM sensitivity – enabling early cancer detection, precise staging, and theranostics (diagnosis + therapy with same ligand).
4. User Case Studies and Technology Updates
Case – Novartis : Market leader (30% share). 2025: Ga-68 DOTATATE (NETs) – diagnostic companion for Lutathera (Lu-177 DOTATATE). PSMA-11 for prostate cancer (diagnostic for Pluvicto). Price: $2,000-5,000 per dose.
Case – Bayer : 2025: F-18 PSMA-1007 (prostate cancer PET). Price: $1,500-3,000 per dose.
Case – China Isotope & Radiation Corporation (CNNC) : Domestic leader (China). 2025: Ga-68 PSMA, F-18 PSMA, Tc-99m labeled RDCs. Price: $500-1,500 per dose (50% below Western).
Case – Grand Pharmaceutical Group : 2025: Ga-68 FAPI (fibroblast activation protein – pan-cancer imaging). Price: $800-2,000 per dose.
Technology Update (Q1 2026) :
- F-18 vs. Ga-68: F-18 (110 min half-life) allows central production, regional distribution (satellite radiopharmacies). Ga-68 (68 min) requires on-site generator or cyclotron. F-18 gaining share.
- Al-F-18 labeling: New chelation chemistry (Al-F-18) simplifies F-18 labeling of peptides (PSMA, FAPI, SSTR). Expands F-18 RDC availability.
- Cu-64 (12.7h half-life) : Ideal for antibody-based RDCs (long circulation). Growing for HER2, PD-L1, CD20 imaging.
5. Exclusive Industry Insight: RDC Theranostic Economics and Clinical Utility
Our analysis reveals that diagnostic RDCs enable theranostics (same ligand for diagnosis + therapy), reducing overall healthcare costs (avoid ineffective therapy, enable personalized treatment).
Proprietary clinical utility analysis (prostate cancer, PSMA-targeted) :
| Parameter | PSMA PET (Diagnostic RDC) | Conventional Imaging (CT, bone scan) | Difference |
|---|---|---|---|
| Sensitivity (biochemical recurrence detection) | 85-95% | 30-50% | PSMA PET 2x more sensitive |
| Specificity | 90-95% | 70-80% | PSMA PET superior |
| Change in management (after PSMA PET) | 40-60% (upstage/downstage) | Baseline | PSMA PET improves treatment decisions |
| Theranostic eligibility (Pluvicto) | Yes (determined by PSMA PET) | No | PSMA PET enables targeted therapy |
| Cost per scan | $1,500-3,000 | $500-1,500 | PSMA PET higher upfront |
| Cost savings (avoided ineffective therapy) | $10,000-50,000 per patient | Baseline | PSMA PET cost-effective |
Key insight: PSMA PET costs $1,500-3,000 more than conventional imaging but saves $10,000-50,000 by avoiding ineffective therapy (enabling Pluvicto or other PSMA-targeted therapy). Highly cost-effective.
Regional Dynamics:
- North America (45% market share): Largest market. US (Novartis, Bayer, AstraZeneca, Eli Lilly, BMS, J&J – PSMA PET, NET PET). High PET/CT density. Reimbursement established (CMS, commercial).
- Europe (25% market share): Germany, France, UK, Italy. Novartis (Lutathera, Pluvicto). Strong theranostics adoption (NETs, prostate).
- Asia-Pacific (25% share, fastest-growing at 15% CAGR): China (Grand Pharma, China Isotope & Radiation, Yantai Dongcheng, Kelun-Biotech, Hengrui, SmartNuclide, Full-Life, Baheal, Yunnan Baiyao, TOT Biopharm, Nuoyu, Foshan Ruidio, Chengdu Yunke, Shandong Andike, Hexin, Sinotau – fastest-growing). Japan, South Korea, India.
- Rest of World (5%): Latin America, Middle East.
Market Outlook 2026–2032
The global diagnostic RDC market is projected to grow at 11.5% CAGR, reaching US$11.16B by 2032. Peptide-conjugated (PRC) fastest-growing (15% CAGR) for theranostics (PSMA, SSTR, FAPI). Small molecule (SMRC) emerging for FAPI (pan-cancer). Prostate cancer (PSMA) largest application (25% share). F-18 gaining share over Ga-68 (longer half-life, regional distribution). Theranostics (diagnostic + therapeutic RDCs) driving growth (Novartis Lutathera/Pluvicto). China fastest-growing (15% CAGR) driven by domestic R&D and PET/CT expansion.
Success requires mastering three capabilities: (1) chelation chemistry (DOTA, NOTA, NODAGA, HBED-CC – stable radionuclide binding), (2) ligand design (PSMA, SSTR, FAPI, HER2 – high affinity, specificity), and (3) theranostic platform (diagnostic + therapeutic isotope pair). Novartis leads commercial segment; Chinese domestic manufacturers (Grand Pharma, CNNC, Yantai Dongcheng, Kelun-Biotech, Hengrui, SmartNuclide, Full-Life, Baheal, Yunnan Baiyao, TOT Biopharm, Nuoyu, Foshan Ruidio, Chengdu Yunke, Shandong Andike, Hexin, Sinotau) fastest-growing.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
